Pacira BioSciences, Inc. (PCRX) – What Are Analysts Saying About This Stock?

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) have been assigned an average recommendation of “Hold” from the eleven research firms that are covering the stock, Marketbeat Ratings reports. Ten analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $33.33.

A number of equities research analysts recently issued reports on PCRX shares. Needham & Company LLC cut shares of Pacira BioSciences from a “buy” rating to a “hold” rating in a research report on Thursday, October 8th. Oppenheimer initiated coverage on shares of Pacira BioSciences in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $32.00 price target for the company. JPMorgan Chase & Co. upgraded shares of Pacira BioSciences from an “underweight” rating to a “neutral” rating and set a $36.50 target price for the company in a report on Thursday, October 8th. Royal Bank Of Canada lifted their price objective on Pacira BioSciences from $25.00 to $36.50 and gave the company a “sector perform” rating in a research report on Friday, October 9th. Finally, Weiss Ratings upgraded Pacira BioSciences from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, October 8th.

Pacira BioSciences Price Performance

Shares of NASDAQ PCRX opened at $36.43 on Friday. The firm’s 50-day simple moving average is $30.17 and its 200 day simple moving average is $25.21. Pacira BioSciences has a fifty-two week low of $18.80 and a fifty-two week high of $36.67. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of 104.09 and a beta of 0.21. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.94 and a current ratio of 5.04.

Pacira BioSciences (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.70 EPS for the quarter, missing the consensus estimate of $0.73 by ($0.03). Pacira BioSciences had a return on equity of 9.68% and a net margin of 1.96%. The firm had revenue of $176.65 million during the quarter, compared to the consensus estimate of $182.87 million. As a group, research analysts anticipate that Pacira BioSciences will post 1.86 earnings per share for the current fiscal year.

Insider Transactions at Pacira BioSciences

In other Pacira BioSciences news, insider Jonathan Slonin sold 3,040 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $23.23, for a total transaction of $70,619.20. Following the transaction, the insider directly owned 216,384 shares of the company’s stock, valued at $5,026,600.32. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Lauren Riker sold 6,000 shares of the business’s stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $36.32, for a total transaction of $217,920.00. Following the sale, the senior vice president directly owned 62,284 shares of the company’s stock, valued at approximately $2,262,154.88. This represents a 8.79% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Pacira BioSciences

A number of hedge funds have recently modified their holdings of the business. Meeder Asset Management Inc. acquired a new position in Pacira BioSciences in the 1st quarter valued at about $46,000. Global Retirement Partners LLC bought a new position in Pacira BioSciences during the 2nd quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Pacira BioSciences during the third quarter worth $51,000. State of Wyoming purchased a new stake in Pacira BioSciences in the second quarter worth $78,000. Finally, PNC Financial Services Group Inc. raised its holdings in Pacira BioSciences by 15.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,751 shares of the company’s stock valued at $85,000 after buying an additional 492 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management and regenerative health solutions. The company’s products are designed to address acute postsurgical pain and osteoarthritis-related pain while supporting efforts to reduce reliance on opioid medications.

Pacira’s lead product is EXPAREL, an extended-release formulation of bupivacaine administered by injection for postsurgical pain management. The company also markets ZILRETTA, an extended-release corticosteroid injection indicated for osteoarthritis knee pain, and iovera°, a cryoanalgesia system that uses controlled cooling to temporarily block peripheral nerves and relieve pain.

Formerly known as Pacira Pharmaceuticals, the company adopted the Pacira BioSciences name to reflect its broader focus on innovative pain and regenerative-health therapies.